$10,000 in Axon Stock a Decade Ago Would Be Worth About $329,000 Today. The Stock Is Down Over the Past Year.

Axon’s Q2 revenue rose 35% YoY to $904M (10th straight quarter above 30%), with software/services up 36% to $398M and connected devices up 35% to $507M. However, adjusted gross margin slipped to 62.9% and GAAP net income was $29M (vs $155M adjusted), while the stock is still down >35% from its Aug. 7, 2025 record close of $870.97—prompting a further pullback despite a raised 2026 revenue growth forecast to 32%–34%. The main issue appears to be valuation/multiple compression (about 75x annualized adjusted earnings), leaving limited room if growth decelerates and margins continue to soften.

Analysis

AXON remains the clearest winner in public-safety tech because the installed base is still monetizing through software attach, not just hardware replacement. The second-order effect is that this model raises the bar for competitors like Motorola Solutions: they can match devices, but it is harder to replicate a high-retention workflow stack once agencies standardize on evidence management. The risk for the ecosystem is that budget-constrained municipalities may stretch replacement cycles if procurement scrutiny rises, which would hit device revenue first and then slow the software flywheel with a lag.

The selloff looks more like multiple compression than a fundamental break, but the distinction matters: the stock is now trading like a company that must keep compounding at a very high rate to justify itself. Over the next 1-3 months, the key catalyst is whether management can preserve growth above the psychological 30% line while stabilizing gross margin; if either slips, the de-rating can continue even if bookings remain healthy. Over 6-18 months, the real risk is GAAP conversion and mix shift: if lower-margin professional services and scaled products keep diluting margins, the market will stop paying for "story" and focus on earnings power.

Consensus is probably missing two things at once: first, the contracted backlog makes near-term revenue less fragile than the chart implies; second, the stock is still expensive enough that a normalizing growth rate could produce another sharp leg down. That argues for treating this as a quality compounder on a watchlist, not a conviction breakout. The move feels partly overdone tactically, but not obviously done structurally until the market sees at least one more quarter of >30% growth with margin stability.

Key Decisions for Investors

• Start only a small AXON position on further weakness or post-earnings stabilization; add on confirmation that revenue growth stays >30% and adjusted gross margin stops slipping. Risk/reward is asymmetrical only if the market re-rates the name back toward peak-multiple territory; downside remains material if growth slows into the 20s.
• Use a defined-risk bull call spread in AXON rather than cash equity for a 6-12 month view. The trade works if the stock grinds higher on continued backlog conversion, while capping loss if valuation compression persists.
• For relative-value exposure, consider long AXON / short MSI as a public-safety-tech pair over the next 1-2 earnings cycles. The thesis is that AXON should outgrow the category, but the short leg offsets broad multiple risk; stop out if AXON growth falls below 30% or MSI shows stronger share gains.
• Set a hard watch level on the next two quarters: revenue growth below 30% or adjusted gross margin below ~62% would invalidate the quality-compounder thesis and likely trigger another de-rating.
• No aggressive momentum chase here; if AXON rallies back quickly without a fundamental catalyst, fade the move rather than add. The stock still behaves like a long-duration asset, so the entry point matters more than the story.